Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
On Wednesday, BMO Capital Markets adjusted its price target for Sarepta Therapeutics (NASDAQ:SRPT), a biopharmaceutical company, from $160.00 to $120.00 while retaining an Outperform rating on the stock. The revision follows recent developments that have raised concerns among investors regarding the company’s future challenges. According to InvestingPro data, the stock has fallen over 61% year-to-date and is currently trading near its 52-week low, suggesting significant investor pessimism. However, analysis indicates the stock may be undervalued at current levels.
The announcement of a new Director at the Center for Biologics Evaluation and Research (CBER), combined with a first-quarter earnings miss and a downward revision of the company’s 2025 financial guidance, has significantly impacted investor sentiment. After the market closed, Sarepta’s valuation seemed to reflect these concerns, with the stock’s price primarily accounting for its phosphorodiamidate morpholino oligomers (PMOs) and largely discounting the potential of Elevidys and the company’s broader pipeline. Despite recent challenges, InvestingPro data shows the company maintains strong fundamentals with a current ratio of 4.2x and impressive revenue growth of 53% over the last twelve months.
Despite the challenges, BMO Capital believes that certain factors could contribute to Sarepta’s stock performance by the end of 2025. These include anticipated growth in Elevidys sales in the second half of 2025, positive readouts from clinical trials for DM1 and FSHD in the same period, and forthcoming regulatory updates on the company’s Limb-girdle muscular dystrophy (LGMD) programs.
The analyst from BMO Capital noted that while it is recognized that restoring investor confidence may take time, the market has not yet fully appreciated the potential positive developments that could drive the stock’s upside by the end of 2025. The revised price target of $120.00 reflects this cautious optimism while acknowledging the near-term headwinds Sarepta is facing, including the 2027 convertible debt obligations.
In other recent news, Sarepta Therapeutics has faced significant challenges impacting its financial outlook and investor sentiment. The company reported a first-quarter 2025 earnings miss, with an earnings per share (EPS) loss of $3.42, contrasting sharply with the forecasted profit of $1.96. Despite this, Sarepta’s revenue surpassed expectations, reaching $774.9 million against an anticipated $695.9 million. However, the company has revised its full-year revenue guidance downward to a range of $2.3 to $2.6 billion. Analysts have responded by adjusting their price targets for Sarepta, with RBC Capital, Cantor Fitzgerald, TD Cowen, and H.C. Wainwright lowering their targets due to concerns over Sarepta’s gene therapy product, Elevidys. RBC Capital now sees a target of $58, Cantor Fitzgerald has set it at $81, TD Cowen at $137, and H.C. Wainwright at $40. These revisions reflect apprehensions about safety concerns, production challenges, and competitive pressures. Despite these setbacks, some analysts, like those from TD Cowen, maintain a positive long-term view, continuing to recommend a Buy rating for Sarepta’s stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.